Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Bachy

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
The Lancet. Haematology|December 22, 2015
Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?Emmanuel Bachy, Bertrand Coiffier
Seminars in Hematology|March 26, 2015
Treatment approach to newly diagnosed diffuse large B-cell lymphomaEmmanuel Bachy, Gilles Salles
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Are we nearing an era of chemotherapy-free management of indolent lymphoma?Emmanuel Bachy, Gilles Salles
Blood|May 17, 2014
Time has come for immunotherapy in PTCLEmmanuel Bachy, Bertrand Coiffier
Blood Advances|May 29, 2026
CAR in R/R FL: is real-world efficacy meeting expectations?Estelle Bourbon, Emmanuel Bachy
Bulletin Du Cancer|December 18, 2021
CAR-T cells, from principle to clinical applicationsEstelle Bourbon, Hervé Ghesquières, Emmanuel Bachy
Expert Review of Hematology|January 15, 2015
Chemotherapy-free treatment in patients with follicular lymphomaClémentine Sarkozy, Gilles Salles, Emmanuel Bachy
Hematology/Oncology Clinics of North America|November 28, 2016
Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?Pierre Sujobert, Gilles Salles, Emmanuel Bachy
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
What is the best first-line treatment strategy for patients with indolent lymphomas?Gilles Salles, Hervé Ghesquières, Emmanuel Bachy
Blood Advances|March 17, 2021
Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survivalEmmanuel Bachy, James R Cerhan, Gilles Salles
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
The Lancet. Haematology|December 22, 2015
Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?Emmanuel Bachy, Bertrand Coiffier
Seminars in Hematology|March 26, 2015
Treatment approach to newly diagnosed diffuse large B-cell lymphomaEmmanuel Bachy, Gilles Salles
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Are we nearing an era of chemotherapy-free management of indolent lymphoma?Emmanuel Bachy, Gilles Salles
Blood|May 17, 2014
Time has come for immunotherapy in PTCLEmmanuel Bachy, Bertrand Coiffier
Blood Advances|May 29, 2026
CAR in R/R FL: is real-world efficacy meeting expectations?Estelle Bourbon, Emmanuel Bachy
Bulletin Du Cancer|December 18, 2021
CAR-T cells, from principle to clinical applicationsEstelle Bourbon, Hervé Ghesquières, Emmanuel Bachy
Expert Review of Hematology|January 15, 2015
Chemotherapy-free treatment in patients with follicular lymphomaClémentine Sarkozy, Gilles Salles, Emmanuel Bachy
Hematology/Oncology Clinics of North America|November 28, 2016
Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?Pierre Sujobert, Gilles Salles, Emmanuel Bachy
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
What is the best first-line treatment strategy for patients with indolent lymphomas?Gilles Salles, Hervé Ghesquières, Emmanuel Bachy
Blood Advances|March 17, 2021
Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survivalEmmanuel Bachy, James R Cerhan, Gilles Salles
Pageof 18